Lanreotide
- Atc Codes:H01CB03
- CAS Codes:127984-74-1#108736-35-2
- PHARMGKB ID:127984-74-1#108736-35-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Somatuline; Belgium: Somatuline; Cyprus: Somatuline; Czech Republic: Somatuline; Denmark: Ipstyl; Estonia: Somatuline; Finland: Somatuline; France: Somatuline; Germany: Somatulina, Somatuline; Greece: Somatuline; Ireland: Somatuline; Italy: Ipstyl; Latvia: Somatuline; Lithuania: Somatuline; Netherlands: Somatuline; Poland: Somatuline; Portugal: Somatulina; Romania: Somatuline; Slovakia: Somatuline; Slovenia: Somatuline; Spain: Somatulina; Sweden: Somatuline; UK: Somatuline.
North America
Canada: Somatuline; USA: Somatuline.
Latin America
Argentina: Somatuline.
Drug combinations
Chemistry
Lanreotide Acetate: C~54~H~69~N~11~O~10~S~2~ x(C~2~H~4~O~2~). Mw: 1096.32 (base compound). (1) L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2→7)-disulfide, acetate; (2) 3-(2-Naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide, cyclic (2→7)-disulfide, acetate. CAS-127984-74-1; CAS-108736-35-2 (lanreotide)(1992).
Pharmacologic Category
Other Miscellaneous Therapeutic Agents; Somatostatin Analog. (ATC-Code: H01CB03).
Mechanism of action
Synthetic octapeptide analog of somatostatin inhibitor of multiple endocrine, neuroendocrine, and exocrine mechanisms. Displays greater affinity for somatostatin type 2 (SSTR2) and type 5 (SSTR5) receptors. Reduces GH secretion and also reduces levels of insulin-like growth factor 1.
Therapeutic use
Long-term treatment of acromegaly in patients who are not candidates for or are unresponsive to surgery and/or radiotherapy.
Pregnancy and lactiation implications
Animal studies demonstrated embryocidal and teratogenic effects, as well as transitory growth retardation. Use in pregnancy only if benefits outweigh potential risks to fetus. Not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to lanreotide, somatostatin (or related peptides), or any component of the formulation. Complicated, untreated lithiasis of the bile ducts.
Warnings and precautions
Might cause cholelithiasis, hyper-/hypoglycemia (use with caution in diabetes), hypothyroidism, cardiac disorders (bradycardia, sinus bradycardia, hypertension). Use with caution in hepatic and renal impairment. Concurrent use with cyclosporine may result in decreased serum levels of cyclosporine. Packaging (needle cover) may contain latex.